Pancreatic Cancer
SALV-ENZA trial
In the multicenter, phase II SALV-ENZA trial, 86 men with biochemically recurrent #prostate_cancer after RP were randomized to either...
ECOG-ACRIN E2211 trial
.png)
In phase II ECOG-ACRIN E2211 trial, the addition of Capecitabine to Temozolomide significantly improved the progression-free survival (PFS) in patients...
NEOPAN trial
In phase III NEOPAN study presented by Dr. Ducreux, FOLFIRINOX improved progression-free survival (PFS) compared to gemcitabine in #locally_advanced unresectable...
FDA approval of bevacizumab biosimilar
On September 28th 2022, the FDA has approved Celltrion’s #bevacizumab biosimilar (bevacizumab-adcd) in six types of cancers which are: metastatic...
.png)